查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485285

口腔黏膜藥物市場 - 按產品類型（片劑、薄膜、液體和噴霧劑）、給藥途徑、適應症（鴉片類藥物依賴性、噁心和嘔吐、勃起功能障礙、神經系統疾病）、配銷通路和預測，2024 - 2032

Oral Transmucosal Drugs Market - By Product Type (Tablet, Film, Liquid & Spray), Route of Administration, Indication (Opioid Dependence, Nausea & Vomiting, Erectile Dysfunction, Neurological Disorders), Distribution Channel & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於該領域的研究和開發迅速發展，2024 年至 2032 年間，全球口腔黏膜藥物市場規模的複合年成長率將達到 6.7%。這種激增可歸因於對新型藥物輸送方法的持續探索以及對非侵入性給藥途徑的日益偏好。例如，2023 年 1 月，馬爾默大學的一組研究人員聲稱，他們有信心透過口腔黏膜的捷徑創造出理想的偏頭痛治療方法。在名為「依來曲坦口腔黏膜遞送治療神經系統疾病」的計畫中，Sabrina Valetti 和她的研究人員同事選擇關注依來曲普坦氫溴酸鹽(EB)，該藥物因其對曲坦類藥物中心臟健康的影響最小而聞名。他們的研究探討了透過口腔黏膜施用依來曲坦作為治療手段的潛力。

研究人員正在深入研究可提高生物利用度和快速起效的創新配方。此外，口腔黏膜藥物治療應用的擴展，從疼痛管理到荷爾蒙療法，正在推動市場成長。此外，黏膜黏附貼片和舌下噴霧劑等技術的進步正在推動患者和醫療保健提供者擴大採用該技術。隨著研究工作的加強，口腔黏膜藥物市場有望大幅擴張，以滿足現代醫療保健不斷變化的需求。

整個口腔黏膜藥物產業根據產品類型、給藥途徑、適應症、配銷通路和地區進行分類。

到 2032 年，薄膜細分市場將出現顯著成長。隨著製劑技術的進步，跨黏膜薄膜可直接透過口腔黏膜有效輸送藥物，繞過胃腸道並確保快速起效。此外，它們的易用性和便攜性使其對不同人群的患者都有吸引力。因此，由於人們越來越喜歡薄膜作為一種方便有效的劑型，口腔黏膜藥物的市場不斷擴大。

從2023年到2032年，頰黏膜領域的口腔黏膜藥物市場佔有率將顯著擴大。此途徑也提高了患者的依從性和便利性，因為它消除了吞嚥藥丸或注射的需要。隨著製藥公司擴大投資開發針對口腔遞送的創新製劑，口腔黏膜藥物的市場不斷擴大，這是由於口腔黏膜作為有效藥物吸收和遞送的有前途途徑的潛力所驅動。

在醫療保健支出增加、慢性病盛行率上升以及老年人口不斷成長的推動下，歐洲遮陽帆市場從 2024 年到 2032 年將呈現出值得稱讚的複合年成長率。此外，有利的政府措施和報銷政策進一步刺激市場成長。歐洲消費者越來越青睞非侵入性給藥方法，例如口腔黏膜製劑，因為它們方便且有效。此外，該地區正在進行的研究和開發工作不斷推出創新產品並擴大治療應用。因此，歐洲的口腔黏膜藥物市場在可預見的未來將持續擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 口腔黏膜藥物的需求不斷成長
      • 藥物傳輸技術的進步
      • 慢性病盛行率增加
    • 產業陷阱與挑戰
      • 藥品核准和商業化的嚴格監管要求
      • 與研發活動相關的高成本
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析
  • 技術景觀
  • 未來市場趨勢

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品類型，2018 年 - 2032 年

  • 主要趨勢
  • 平板電腦
  • 電影
  • 液體和噴霧
  • 其他產品類型

第 6 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

  • 主要趨勢
  • 舌下黏膜
  • 頰粘膜
  • 其他給藥途徑

第 7 章：市場估計與預測：按指標分類，2018 年 - 2032 年

  • 主要趨勢
  • 鴉片類藥物依賴
  • 噁心和嘔吐
  • 性功能障礙
  • 神經系統疾病
  • 其他適應症

第 8 章：市場估計與預測：按配銷通路，2018 年 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Aquestive Therapeutics, Inc.
  • C.L.Pharm Co., Ltd.
  • CURE Pharmaceutical
  • IntelGenx Corp
  • Jazz Pharmaceuticals
  • NAL Pharma
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ZIM Laboratories Limited.
簡介目錄
Product Code: 8477

Global Oral Transmucosal Drugs Market Size will witness 6.7% CAGR between 2024 and 2032 due to the burgeoning research and development in the field. This surge can be attributed to the continuous exploration of novel drug delivery methods and the growing preference for non-invasive routes of administration. For instance, in January 2023, a team of researchers at Malmo University claimed that they were confident in their ability to create an ideal migraine treatment through a shortcut in the oral mucous membrane. In their project titled "Oral Transmucosal Delivery of Eletriptan for Neurological Diseases," Sabrina Valetti and her fellow researchers opted to focus on eletriptan hydrobromide (EB), known for its minimal impact on cardiac health among triptans. Their study explored the potential of administering eletriptan via the oral mucosa as a means of treatment.

Researchers are delving into innovative formulations that offer enhanced bioavailability and rapid onset of action. Additionally, the expansion of therapeutic applications for oral transmucosal drugs, ranging from pain management to hormonal therapies, is propelling market growth. Moreover, advancements in technology, such as mucoadhesive patches and sublingual sprays, are driving increased adoption among patients and healthcare providers alike. As research efforts intensify, the Oral Transmucosal Drugs Market is poised for significant expansion, catering to the evolving needs of modern healthcare.

The overall Oral Transmucosal Drugs Industry is classified based on the product type, route of administration, indication, distribution channel, and region.

The films segment will register a significant growth rate by 2032. These thin, dissolvable strips offer a convenient and discreet alternative to traditional routes of drug administration. With advancements in formulation technology, transmucosal films provide efficient drug delivery directly through the oral mucosa, bypassing the gastrointestinal tract and ensuring rapid onset of action. Moreover, their ease of use and portability make them appealing to patients across various demographics. As a result, the market for oral transmucosal drugs continues to expand, driven by the growing preference for films as a convenient and effective dosage form.

The oral transmucosal drugs market share from the buccal mucosa segment will expand appreciably from 2023 to 2032. Buccal administration offers direct access to the bloodstream, bypassing the gastrointestinal tract and liver metabolism, leading to improved bioavailability and faster onset of action. This route also enhances patient compliance and convenience, as it eliminates the need for swallowing pills or injections. With pharmaceutical companies increasingly investing in developing innovative formulations tailored for buccal delivery, the market for oral transmucosal drugs continues to expand, driven by the potential of buccal mucosa as a promising route for efficient drug absorption and delivery.

Europe shade sails market will showcase a commendable CAGR from 2024 to 2032, driven by increasing healthcare expenditures, rising prevalence of chronic diseases, and a growing geriatric population. Additionally, favorable government initiatives and reimbursement policies further stimulate market growth. European consumers increasingly favor non-invasive drug delivery methods, such as oral transmucosal formulations due to their convenience and effectiveness. Moreover, ongoing research and development efforts in the region continue to introduce innovative products and expand therapeutic applications. As a result, the Oral Transmucosal Drugs Market in Europe is poised for continued expansion in the foreseeable future.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising demand for oral transmucosal drugs
      • 3.2.1.2 Advancements in drug delivery technologies
      • 3.2.1.3 Increasing prevalence of chronic diseases
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory requirements for drug approval and commercialization
      • 3.2.2.2 High cost associated with research and development activities
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Technological landscape
  • 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tablets
  • 5.3 Films
  • 5.4 Liquid & spray
  • 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Sublingual mucosa
  • 6.3 Buccal mucosa
  • 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Opioid dependence
  • 7.3 Nausea and vomiting
  • 7.4 Erectile dysfunction
  • 7.5 Neurological disorders
  • 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Aquestive Therapeutics, Inc.
  • 10.2 C.L.Pharm Co., Ltd.
  • 10.3 CURE Pharmaceutical
  • 10.4 IntelGenx Corp
  • 10.5 Jazz Pharmaceuticals
  • 10.6 NAL Pharma
  • 10.7 Novartis AG
  • 10.8 Pfizer Inc.
  • 10.9 Teva Pharmaceutical Industries Ltd.
  • 10.10 ZIM Laboratories Limited.